Nir Barzilai MD.
Company: Albert Einstein College of Medicine
Job title: Director, Institute for Aging Research
Dr. Barzilai is a chaired Professor of Medicine and Genetics and Director of the biggest Center in the world to study the Biology of Aging. He is the recipient of an NIH Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. He is a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award. He is leading the TAME (Targeting/Taming Aging with Metformin) multi central study to prove that concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions. He is a founder of CohBar Inc. (now public company) and Medical Advisor for Life Biosciences. He is on the board of AFAR and CohBar He has been featured in major papers, TV program and documentaries (TEDx and TEDMED) and has been Consulting or presented the promise for targeting aging at The Singapore Prime Minister Office, several International Banks, Pepsico, Milkin Institute, The Economist and Wired Magazine.
TAMEing Aging 1:00 pm
Exploring metformin – a generic, cheap and safe drug used to treat Type 2 diabetes mellitus (T2DM), which targets biology of aging, extends health span and life span in animals Showing that metformin targets this biology in muscle and adipose tissue of elderly Numerous clinical and observational studies in humans show that metformin therapy delays…Read more
day: Day Two
Keynote Panel: A Therapeutic Revolution Against Aging – Bridging the Gaps & Opportunities 9:15 am
Exploring what we know and what we still don’t know about the aging process Exploring the targeting of aging as a disease vs. aging as a common factor for different conditions Analyzing the current R&D landscape for anti-aging therapeutics Key challenges in discovery and progression of pipelines Greatest promises for healthspan improvement Addressing and dealing…Read more
day: Day One